Rating Rationale
September 09, 2022 | Mumbai
Valiant Laboratories Limited
'CRISIL A-/Stable/CRISIL A2+' assigned to Bank Debt
 
Rating Action
Total Bank Loan Facilities RatedRs.50 Crore
Long Term RatingCRISIL A-/Stable (Assigned)
Short Term RatingCRISIL A2+ (Assigned)
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has assigned its CRISIL A-/Stable/CRISIL A2+ ratings to the bank facilities of Valiant Laboratories Limited (VLL).

 

The ratings reflect the strong marked position marked by established customer relationship and diversified product basket, experienced management, and strong financial risk profile. These strengths are partially offset by its susceptibility to fluctuations in raw material prices, intense competition and regulatory risks, and its working capital-intensive operations.

Analytical Approach

Unsecured loan of Rs 59.4 crore from the promoters has been treated as debt.

Key Rating Drivers & Detailed Description

Strengths:

Established customer relationships and diversified product basket: VLL has established presence in the active pharmaceutical ingredient (API) manufacturing business. It has a diverse product portfolio which includes Acetic Acid, Para Nitro Phenol, Para Amino Phenol, Chlorzoxazone and Paracetamol, which finds application in various drugs. This helps mitigate risks arising from substitutes or decline in demand. VLL has established healthy and long-term relationship with various customers across India. Its top customers contribute to about 36% revenues in fiscal 2022. CRISIL believes that VLL’s established industry presence, diversified product basket and long and established relations with customers, bolsters its business risk profile.

 

Experienced management: VLL is part of the Valiant group and is step down subsidiary of Valiant Organics Ltd (VOL, rated 'CRISIL A/Stable/CRISIL A1'). VOL is also a major supplier for VLL. Promoters have been engaged in the chemical intermediates business for over three decades which has enabled them to develop strong understanding of market dynamics and establish healthy relations with customers and suppliers. This has helped VLL scale up rapidly post acquisition by VOL in 2019. Revenues have increased steadily for past 3 years to Rs 290 crores in Fiscal 2022 from Rs 91 crores in Fiscal 2020.

 

Strong financial risk profile: Low reliance on external funds has kept the capital structure healthy, as indicated by gearing of 0.85 time and total outside liabilities to adjusted net worth ratio of 1.44 times as on March 31, 2022, coupled with strong net worth of Rs. 71.5 crores. Debt protection metrics have also been healthy backed by low debt. The interest coverage and net cash accrual to total debt ratio stood at 658 times and 0.48 time, respectively, for fiscal 2022. Low debt and healthy accretion to reserve should keep the financial risk profile healthy over the medium term.

 

Weaknesses:

Susceptibility to fluctuations in raw material prices, intense competition and regulatory risks: The raw material prices are volatile, and their availability is subject to market conditions. The operating margin of VLL has been volatile in range of 7-26% over past three fiscals, on account of fluctuations in raw material prices, which the company can pass on after a lag. Players in the pharmaceutical industry are susceptible to regulatory changes with respect to price controls and approvals. Moreover intense competition in the pharmaceutical industry further restricts the bargaining power.  

 

Working capital-intensive operations: Gross current assets were at 112-161 days over the three fiscals through 2022. The large working capital requirement stem from sizeable receivables of 139 days and moderate inventory of 23 days. The receivables are high at the end of the fiscal due to high year-end sales and it provides extensive credit to longstanding customers. The working capital cycle will remain a key monitorable.

Liquidity: Strong

VLL has strong liquidity driven by expected cash accruals of Rs 24-26 crores per annum in fiscals 2023 and 2024 against nil debt repayments. VLL’s fund-based limits has been unutilized over the 12 months ended June 2022. Cash and cash equivalents were about Rs.20 crores. Current ratio was healthy at 3.56 times as on March 31, 2022. Unsecured loans of Rs 59 crores provides support for prudent working capital management. With a gearing of 0.85 times, VLL has sufficient gearing headroom, to raise additional debt if required. Its cash accruals and bank lines are expected to meet its incremental working capital requirements.

Outlook: Stable

VLL will continue to benefit from the extensive experience of its promoters, established relationships with clients and healthy financial profile of the company.

Rating Sensitivity Factors

Upward factors

  • Sustained revenue growth and stable operating margin, leading to cash accrual of more than Rs 40 crore
  • Improvement in the working capital cycle

 

Downward factors

  • Decline in operating profitability leading to net cash accrual falling below Rs 20 crore
  • Large debt-funded capital expenditure or increase in working capital requirement weakening the capital structure

About the Company

VLL was established by Mr Shantilal Vora in 1982 as a partnership firm named Bharat Chemicals and was reconstituted as a closely held public limited with the current name in August 2021. It is 63% owned by Dhanvallabh Ventures LLP, a step-down subsidiary of Valiant Organics Ltd (VOL). VLL manufactures active pharmaceutical ingredients (API) such as para nitro phenol and salt, paracetamol, diluted acetic acid at its facility in Tarapur, Maharashtra. Currently the operations are  being managed by Mr Santosh Vora (Son of Mr Shantilal Vora ) who is is the director in the company.

Key Financial Indicators

As on/for the period ended March 31

Unit

2022

2021

Operating income

Rs crore

290.02

180.76

Reported profit after tax

Rs crore

27.00

31.83

PAT margin

%

9.31

17.63

Adjusted debt/adjusted networth

Times

0.85

0.00

Interest coverage

Times

658.04

-

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings' complexity levels are assigned to various types of financial instruments. The CRISIL Ratings' complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL Ratings' complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of instrument(s)

ISIN

Name of instrument

Date of allotment

Coupon rate (%)

Maturity date

Issue size (Rs.Crore)

Complexity

level

Rating assigned with outlook

NA

Cash Credit

NA

NA

NA

20

NA

CRISIL A-/Stable

NA

Letter of Credit

NA

NA

NA

30

NA

CRISIL A2+

Annexure - Rating History for last 3 Years
  Current 2022 (History) 2021  2020  2019  Start of 2019
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT 20.0 CRISIL A-/Stable   --   --   --   -- --
Non-Fund Based Facilities ST 30.0 CRISIL A2+   --   --   --   -- --
All amounts are in Rs.Cr.
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Name of Lender Rating
Cash Credit 20 Kotak Mahindra Bank Limited CRISIL A-/Stable
Letter of Credit 30 Kotak Mahindra Bank Limited CRISIL A2+

This Annexure has been updated on 09-Sep-2022 in line with the lender-wise facility details as on 09-Sep-2022 received from the rated entity.

Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings
CRISILs Bank Loan Ratings - process, scale and default recognition
The Rating Process
Understanding CRISILs Ratings and Rating Scales
CRISILs Approach to Recognising Default
Criteria for Notching up Stand Alone Ratings of Companies based on Parent Support

Media Relations
Analytical Contacts
Customer Service Helpdesk

Aveek Datta
Media Relations
CRISIL Limited
M: +91 99204 93912
B: +91 22 3342 3000
AVEEK.DATTA@crisil.com

Prakruti Jani
Media Relations
CRISIL Limited
M: +91 98678 68976
B: +91 22 3342 3000
PRAKRUTI.JANI@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Rahul Subrato Kumar Guha
Director
CRISIL Ratings Limited
D:+91 22 4097 8320
rahul.guha@crisil.com


Ankita Gupta
Associate Director
CRISIL Ratings Limited
D:+91 22 4097 8104
ankita.gupta@crisil.com


Himanshu Khare
Senior Rating Analyst
CRISIL Ratings Limited
B:+91 22 3342 3000
Himanshu.Khare@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.


For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL’s privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale (‘report’) that is provided by CRISIL Ratings Limited (‘CRISIL Ratings’). To avoid doubt, the term ‘report’ includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, ‘CRISIL Ratings Parties’) guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to:
https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

 

 

CRISIL Ratings uses the prefix ‘PP-MLD’ for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html